Endothelin-1 is significantly elevated in plasma of patients with vitiligo treated with psoralen plus ultraviolet A1

Autor:	M. A. Habib, Ekramy A. El-Khateeb, M. B. Abdel‐Naser, T. H. Sallam
Rok vydání:	2006
Předmět:	medicine.medical_specialty Ultraviolet a1 business.industry medicine.medical_treatment Dermatology Vitiligo medicine.disease Endothelin 1 Gastroenterology chemistry.chemical_compound chemistry Psoriasis Internal medicine PUVA therapy Blood plasma medicine business Pigmentation disorder Psoralen
Zdroj:	Clinical and Experimental Dermatology. 31:571-575
ISSN:	1365-2230 0307-6938
DOI:	10.1111/j.1365-2230.2006.02148.x
Popis:	Summary Background. Recent evidence suggests that systemic psoralen plus ultraviolet A (PUVA) therapy may have a stimulatory effect on melanocytes, not only locally but also systemically. Aim. We aimed to assess endothelin-1 (ET-1), a potent melanocyte mitogen, in plasma of PUVA-treated paients with vitiligo. Methods. ET-1 was sequentially assessed (using ELISA) in patients with nonsegmental vitiligo treated with PUVA (n = 20), at 8, 16 and 24 h following the PUVA session. Evaluations took place at 0, 1 and 3 months of therapy. Patients with psoriasis (n = 15) treated identically and healthy subjects not receiving any therapy (n = 15) served as controls. Vitiligo Area Scoring Index (VASI) and Psoriasis Area Severity Index (PASI) scores were simultaneously evaluated. Results. ET-1 was significantly lower in vitiligo than in psoriasis at month 0 (8.2 ± 3.6 vs. 13.7 ± 5.4 pg/mL; P = 0.03) and it was significantly higher in both than in healthy controls at all time points of the PUVA sessions (P 0.05). VASI score significantly decreased at month 3 (19 ± 9.6 vs. 11.9 ± 7.3; P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c0acc4025e375d48ee2f8bbbd50c7148 https://doi.org/10.1111/j.1365-2230.2006.02148.x Zobrazit plný text záznamu Plný text ve formátu PDF